Literature DB >> 23219773

Thrombotic recurrences and bleeding events in APS vascular patients: a review from the literature and a comparison with the APS Piedmont Cohort.

M Bazzan1, A Vaccarino, S Stella, M T Bertero, R Carignola, B Montaruli, D Roccatello, Y Shoenfeld.   

Abstract

In APS vascular patients, thrombotic recurrences are more frequent than in non-APS thrombotic patients. To better define this clinical setting, a systematic review of the literature after 1999 was performed: 8 cohort studies (including the recent APS Piedmont Cohort) and 6 intervention studies were selected and evaluated. Thrombotic recurrences, bleeding events, therapeutic strategies, antiphospholipid (aPL) profile, inherited and acquired risk factors (when present) were calculated and compared. Emerging risk factors for thrombotic recurrences include withdrawal of oral anticoagulant therapy (OAT), high intensity OAT (INR range 3-4), aPL profile (triple positivity, Miyakis types 1 and 2a profiles) and association with inherited or acquired pro-thrombotic risk factors. Moreover, there are evidences that high risk (mainly for aPL profile) APS vascular patients have a high recurrence rate in spite of correct OAT treatment. Clinical trials in this clinical setting are needed.
Copyright © 2012 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23219773     DOI: 10.1016/j.autrev.2012.11.007

Source DB:  PubMed          Journal:  Autoimmun Rev        ISSN: 1568-9972            Impact factor:   9.754


  10 in total

Review 1.  Piedmont and Aosta Valley inter-regional network in the context of the Italian National Network for rare diseases.

Authors:  Simone Baldovino; Elisa Menegatti; Vittorio Modena; Maria Maspoli; Flavia Avanzi; Dario Roccatello
Journal:  Blood Transfus       Date:  2014-04       Impact factor: 3.443

Review 2.  Autoimmunity in 2013.

Authors:  Carlo Selmi
Journal:  Clin Rev Allergy Immunol       Date:  2014-08       Impact factor: 8.667

3.  Soluble analog of ApoER2 targeting beta2-glycoprotein I in immune complexes counteracts hypertension in lupus-prone mice with spontaneous antiphospholipid syndrome.

Authors:  A Kolyada; Q Ke; I Karageorgos; P Mahlawat; D A Barrios; P M Kang; N Beglova
Journal:  J Thromb Haemost       Date:  2016-05-03       Impact factor: 5.824

4.  Systemic lupus erythematosus and thrombosis.

Authors:  Mario Bazzan; Antonella Vaccarino; Fabio Marletto
Journal:  Thromb J       Date:  2015-04-23

Review 5.  Treatment of Thrombotic Antiphospholipid Syndrome: The Rationale of Current Management-An Insight into Future Approaches.

Authors:  Cecilia Beatrice Chighizola; Tania Ubiali; Pier Luigi Meroni
Journal:  J Immunol Res       Date:  2015-05-05       Impact factor: 4.818

6.  Dimerized Domain V of Beta2-Glycoprotein I Is Sufficient to Upregulate Procoagulant Activity in PMA-Treated U937 Monocytes and Require Intact Residues in Two Phospholipid-Binding Loops.

Authors:  Alexey Kolyada; David A Barrios; Natalia Beglova
Journal:  Antibodies (Basel)       Date:  2017-06-02

7.  Acute myocardial infarction in a patient positive for lupus anticoagulant: a case report.

Authors:  Kota Murai; Kenji Sakata; Tadatsugu Gamou; Yoji Nagata; Hayato Tada; Masaya Shimojima; Hirofumi Okada; Kenshi Hayashi; Masa-Aki Kawashiri
Journal:  BMC Cardiovasc Disord       Date:  2019-07-12       Impact factor: 2.298

8.  A challenging case of neuropsychiatric systematic lupus erythematosus with recurrent antiphospholipid- related stroke: A case report and literature review.

Authors:  Yu-Cheng Shih; Yang-Hao Ou; Shu-Wei Chang; Chih-Ming Lin
Journal:  Neurol Int       Date:  2019-09-18

9.  Patterns of Recurrent Thrombosis in Primary Antiphospholipid Syndrome-Multicenter, Real-Life Long-Term Follow-Up.

Authors:  Stanley Niznik; Micha J Rapoport; Orly Avnery; Aharon Lubetsky; Soad Haj Yahia; Martin H Ellis; Nancy Agmon-Levin
Journal:  Front Immunol       Date:  2022-04-19       Impact factor: 8.786

10.  Incidence of thromboembolic events in asymptomatic carriers of IgA anti ß2 glycoprotein-I antibodies.

Authors:  Carlos Tortosa; Oscar Cabrera-Marante; Manuel Serrano; José A Martínez-Flores; Dolores Pérez; David Lora; Luis Morillas; Estela Paz-Artal; José M Morales; Daniel Pleguezuelo; Antonio Serrano
Journal:  PLoS One       Date:  2017-07-20       Impact factor: 3.240

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.